Forte Biosciences announced a definitive agreement to be acquired by argenx for $77.00 per share in cash via a tender offer followed by a merger, leaving Forte as a wholly owned subsidiary. The offer is subject to a majority tender, regulatory approvals, and other customary conditions, with no financing condition. Equity awards and certain warrants will be cashed out pursuant to the agreement terms. In support of the transaction, Forte’s directors and executive officers, holding about 1% of shares, signed Tender and Support Agreements to tender their shares and, if necessary, vote for the merger, subject to customary exceptions.
Agreement 1: Forte Biosciences to Be Acquired by argenx in $77-Per-Share Tender Offer and Merger
- Agreement type: Agreement and Plan of Merger
- Counterparty: argenx
- Signed / Effective: Jul 26 2026 / Jul 26 2026
- Duration / Termination: Until closing
- Reason: Provide cash exit and align Forte with argenx resources
Agreement 2: Forte Biosciences Directors Sign Tender and Support Agreements Backing argenx Deal
- Agreement type: Tender and Support Agreements
- Counterparty: argenx and Avena Merger Sub
- Signed / Effective: Jul 26 2026 / Jul 26 2026
- Duration / Termination: Until merger completion or termination
- Reason: Lock in key holder support for transaction
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.